ScreenPoint Medical Partners with Microsoft to Enhance Breast AI Access via Precision Imaging Network
ScreenPoint Medical Teams Up with Microsoft for Breast AI
In a significant leap forward for healthcare technology, ScreenPoint Medical has announced a commercial agreement that allows its Transpara® breast-imaging AI to be integrated into the Precision Imaging Network, part of Microsoft for Healthcare. This collaboration marks the introduction of advanced artificial intelligence capabilities that aim to transform the breast cancer detection process for medical professionals.
Streamlining Access to Breast AI Tools
The integration of ScreenPoint Medical's Transpara with Precision Imaging Network is set to improve how healthcare providers access AI tools specifically designed for breast imaging. By leveraging this partnership, the company is not only enhancing workflow efficiency but also supporting clinical decision-making at scale.
ScreenPoint Medical has identified Precision Imaging Network as a pivotal partner in facilitating the growth and integration of the Transpara Breast AI portfolio, which serves multiple breast imaging modalities, including mammography. This new partnership is especially beneficial for healthcare organizations that require cloud-enabled access to sophisticated AI tools, seamlessly integrating them into their existing clinical frameworks.
The Importance of Advanced AI in Breast Imaging
Breast cancer remains one of the most common cancers affecting women worldwide. With Transpara, radiologists gain access to a powerful tool that acts as a 'second pair of eyes,' detecting abnormalities earlier and helping reduce the workload associated with traditional screening methods. It is currently recognized as one of the most clinically validated Breast AI solutions in the market.
ScreenPoint Medical aims to translate cutting-edge machine learning research into an accessible platform for radiologists, which not only helps in early cancer detection but also enhances the general confidence in diagnosis. The ability to accurately identify risks and opportunities in breast imaging can significantly shape patient outcomes, leading to more personalized and effective care plans.
Comments from Leadership
On this exciting announcement, Pieter Kroese, CEO of ScreenPoint Medical, stated, "Our mission is to improve breast cancer detection and empower clinical teams with cutting-edge technology. Our collaboration with Precision Imaging Network enables us to broaden access to the Transpara Breast AI portfolio and help providers adopt artificial intelligence in a way that aligns with their specific operational and IT environments."
Additionally, Vikram Chhabra, General Manager of Diagnostic Solutions at Microsoft, commented on the significance of this collaboration: "Healthcare organizations are seeking solutions that simplify clinical workflows and support better patient care. By integrating Transpara solutions with Precision Imaging Network, ScreenPoint Medical offers providers an efficient pathway to access breast imaging decision support while taking advantage of the security and scalability of Microsoft's for Healthcare platform."
About ScreenPoint Medical
In a relentless fight against breast cancer, ScreenPoint Medical focuses on translating opportunities into tangible health outcomes through AI-powered technology. The company's flagship product, Transpara®, is specifically designed for every stage of the breast imaging continuum. From improving consistency in readings to enhancing patient experience, the technology directly impacts healthcare delivery positively.
With a proven track record in research and innovation, the Transpara® Breast AI solution is trusted by healthcare professionals worldwide, reaffirming ScreenPoint Medical's commitment to leading advancements in breast health.
As breast cancer screening continues to evolve, ScreenPoint Medical's partnership with Microsoft positions it at the forefront of healthcare technology, holding the potential to revolutionize how breast cancer detection is approached and managed across diverse clinical settings.